PSMA Ligands Commonly Used in Clinical Practice for Imaging and Therapy
| Ligand | Label | Imaging or therapy | Advantages | Disadvantages |
| PSMA-11 (PSMA-HBED-CC) (12) | 68Ga | Imaging | Most widely used in literature; European Medicines Agency and Food and Drug Administration approval | 68Ga-related disadvantages; high accumulation in urinary tract |
| PSMA-617 (13) | 68Ga | Imaging and therapy | Reduced kidney uptake compared with PSMA-11 | 68Ga-related disadvantages; slightly slower tracer kinetics than for PSMA-11; high accumulation in urinary tract |
| PSMA-I&T (14) | 68Ga | Imaging and therapy | Reduced hepatic uptake compared with PSMA-11 | 68Ga-related disadvantages; lower lesion binding and higher background than for PSMA-11 |
| DCFPyL (11) | 18F | Imaging | Low hepatic uptake | High accumulation in urinary tract |
| PSMA-1007 (15) | 18F | Imaging | Low accumulation in urinary tract | High hepatic uptake; higher number of PSMA-positive lesions attributed to benign origin* |
| rhPSMA-7 (16) | 18F, 68Ga | Imaging and therapy | Radiohybrid concept; low accumulation in urinary tract with 18F | Higher number of PSMA-positive lesions attributed to benign origin* |
↵* Compared with 68Ga-PSMA-11 (e.g., ganglia, unspecific bone lesions, unspecific lymph nodes)